000			01989 a2200577 4500
005			20250518013427.0
264		0	_c20190923
008			201909s 0 0 eng d
022			_a2473-9537
024	7		_a10.1182/bloodadvances.2018019422 _2doi
040			_aNLM _beng _cNLM
100	1		_aKater, Arnon P
245	0	0	_aObinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. _h[electronic resource]
260			_bBlood advances _c12 2018
300			_a3566-3571 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAntibodies, Monoclonal, Humanized _xadverse effects
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aBridged Bicyclo Compounds, Heterocyclic _xtherapeutic use
650	0	4	_aDrug Administration Schedule
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aLeukemia, Lymphocytic, Chronic, B-Cell _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm, Residual
650	0	4	_aRemission Induction
650	0	4	_aRisk Factors
650	0	4	_aSulfonamides _xtherapeutic use
650	0	4	_aTumor Lysis Syndrome _xetiology
700	1		_aKersting, Sabina
700	1		_avan Norden, Yvette
700	1		_aDubois, Julie
700	1		_aDobber, Johan A
700	1		_aMellink, Clemens H
700	1		_aEvers, Ludo M
700	1		_aCroon-de Boer, Fransien
700	1		_aSchreurs, John
700	1		_avan der Spek, Ellen
700	1		_aVisser, Hein
700	1		_aIdink, Cecile
700	1		_aWittebol, Shulamiet
700	1		_aHoogendoorn, Mels
700	1		_aTonino, Sanne H
700	1		_aMobasher, Mehrdad
700	1		_aLevin, Mark-David
773	0		_tBlood advances _gvol. 2 _gno. 24 _gp. 3566-3571
856	4	0	_uhttps://doi.org/10.1182/bloodadvances.2018019422 _zAvailable from publisher's website
999			_c29165057 _d29165057